1. Advanced Preconditioning: Impella 5.5 Support for Decompensated Heart Failure Before Left Ventricular Assist Device Surgery.
- Author
-
König T, Hanke JS, Dogan G, Kempf T, Sieweke JT, Schäfer A, Bauersachs J, Schmitto JD, and Napp LC
- Subjects
- Hemodynamics, Humans, Heart Failure diagnosis, Heart Failure therapy, Heart-Assist Devices
- Abstract
Left ventricular assist devices (LVAD) are increasingly used in patients with advanced heart failure, and available devices and surgical techniques have strongly evolved over time. Adequate recompensation of patients before surgery is important for optimal surgical outcomes. However, patients with terminal heart failure frequently suffer from cardiorenal syndrome, which complicates recompensation by medical means. Here, we report on the use of an Impella 5.5 microaxial pump for supporting a patient with severely decompensated heart failure before LVAD implantation, which resulted in hemodynamic stabilization and effective recompensation prior to surgery., Competing Interests: Declaration of competing interest TK and JSH have nothing to disclose related to this article. JTS received travel support from Abiomed. AS received speaker honoraria and travel support from Abiomed. JB received honoraria for lectures and/or consulting from: Novartis, BMS, Pfizer, Vifor, Bayer, Servier, Orion, CVRx, MSD, Boehringer Ingelheim, AstraZeneca, Abiomed, Abbott, Medtronic; and institutional research support from Zoll, CVRx, Bayer, Vifor, Abiomed, Medtronic. GD and JDS are consultants to Abbott and Medtronic. LCN received research funding, lecture, consulting and proctoring honoraria and travel support from Abiomed and lecture honoraria from Abbott, Maquet and Orion. Other relationships beyond the topic of this letter exist., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF